Across multiple ACG 2025 reports, tenapanor (50 mg BID) showed consistent benefit for IBS-C—especially bloating. In a pooled post hoc analysis of 3 trials (n=1253 with moderate-to-severe baseline bloating), tenapanor delivered a greater 12-week reduction vs placebo (LS mean change −2.66 vs −2.10; difference −0.57; P=.0003) with faster onset (median time to ≥30% bloating improvement 5 vs 8 weeks; P<.0001).
